期刊
EXPERT REVIEW OF PROTEOMICS
卷 11, 期 2, 页码 179-205出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14789450.2014.894466
关键词
colorectal cancer; genomics; methylomics; miRNAomics; proteomics; transcriptomics
资金
- NHMRC [603130, 1017078]
- National 973 Basic Research Program of China [2013CB911300, 2012CB518900, 2011CB910703]
- National Science and Technology Major Project [2011ZX09302-001-01, 2012ZX09501001-003]
- Chinese NSFC [81172173, 81225015]
Colorectal cancer (CRC) is the second most common cancer in females and the third in males. Since CRC is often diagnosed at an advanced stage when prognosis is poor, identification of biomarkers for early diagnosis is urgently required. Recent advances in proteomics, genomics and transcriptomics have facilitated high-throughput profiling of data generated from CRC-related genes and proteins, providing a window of information for biomarker discovery and validation. However, transfer of candidate biomarkers from bench to bedside remains a dilemma. In this review, we will discuss emerging proteomic technologies and highlight various sample types utilized for proteomics-based identification of CRC biomarkers. Moreover, recent breakthroughs in genomics and transcriptomics for the identification of CRC biomarkers, with particular emphasis on the merits of emerging methylomic and miRNAomic strategies, will be discussed. Integration of proteomics, genomics and transcriptomics will facilitate the discovery and validation of CRC biomarkers leading to the emergence of personalized medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据